Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SELLAS Life Sciences GroupSLS -5.24%25 Earnings per Share (Diluted) is $-0.23 as of Mar. 2026. GuruFocus rates SLS with a GF Score™ of 25/100. Among 1,167 Biotechnology companies, SELLAS Life Sciences Group ranks better than 82.35% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was 46.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 32.30% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 63.20% per year.
During the past 13 years, SELLAS Life Sciences Group's highest 3-Year average EPS without NRI Growth Rate was 83.80% per year. The lowest was -81.20% per year. And the median was 34.00% per year.
SELLAS Life Sciences Group (NAS:SLS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
SELLAS Life Sciences Group Earnings per Share (Diluted) Related Terms
SELLAS Life Sciences Group Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for SELLAS Life Sciences Group's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group Earnings per Share (Diluted) Chart
SLS vs MBX, BHVN, PHVS: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, SELLAS Life Sciences Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's PE Ratio distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's PE Ratio falls into.
SELLAS Life Sciences Group Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
SELLAS Life Sciences Group's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.23 mean?
SELLAS Life Sciences Group (SLS) has a Earnings per Share (Diluted) of $-0.23 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on SELLAS Life Sciences Group and its competitors. According to the industry distribution chart, SELLAS Life Sciences Group ranks #206 out of 1167 companies in the Biotechnology industry, placing it in the top 17.7%.
Is SELLAS Life Sciences Group's Earnings per Share (Diluted) too high?
SELLAS Life Sciences Group's current Earnings per Share (Diluted) is $-0.23. Based on the distribution chart, SELLAS Life Sciences Group ranks #206 out of 1167 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Earnings per Share (Diluted) compare to MBX and BHVN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #206 out of 1167 companies for Earnings per Share (Diluted). This places SELLAS Life Sciences Group in the top 18% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 16.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.60, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current Earnings per Share (Diluted) is $-0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Earnings per Share (Diluted) of $-0.23. The current Earnings per Share (Diluted) is $-0.23. SELLAS Life Sciences Group's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Earnings per Share (Diluted) is $-0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
